Risk factor
Poor trading liquidity
Profitability factor
Overvalued vs peers
About
Established in 2004 and headquartered in Miaoli County, Taiwan, Savior Lifetec Corporation operates as a specialized pharmaceutical company, focusing on injectable products. The firm is dedicated to the development and manufacturing of sterile active pharmaceutical ingredients (APIs) and complete finished dosage formulations. Its current product portfolio encompasses imipenem and cilastatin sodium, an antibacterial agent administered intravenously, and meropenem, a beta-lactamase resistant carbapenem antibiotic for parenteral use. Additionally, Savior Lifetec provides ertapenem, another carbapenem effective against a range of gram-negative and gram-positive aerobic and anaerobic bacteria. Looking to the future, their development pipeline includes SLC-006, aimed at treating prostate cancer, endometriosis, and uterine leiomyoma, alongside a sterile paliperidone palmitate API for the management of schizophrenia.
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITDA,